Investing.com – Evercore ISI raised its price target on West Pharmaceutical Services shares (NYSE:WST) to $390 from $320 while maintaining an Outperform rating.
The firm increased its price target following the company’s recent financial results. The new target implies approximately 45 times the 2026 price-to-earnings ratio and roughly 29 times EBITDA. The stock currently trades at a P/E ratio of 45.5, though InvestingPro data suggests the shares may be overvalued relative to its Fair Value estimate, placing it among stocks on the Most Overvalued list.
Evercore ISI stated the company needed a strong result to help investors look past sentiment concerns related to GLP-1 products. The firm said West Pharmaceutical delivered such a result.
The research firm said it is encouraged by the company’s update. Evercore ISI noted its conviction is strengthened by West Pharmaceutical’s performance and outlook excluding GLP-1 products.
West Pharmaceutical Services manufactures components and systems for injectable drug delivery. The company maintains a market capitalization of $22.35 billion and boasts a remarkable 33-year streak of consecutive dividend increases, according to InvestingPro Tips. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for WST and 1,400+ other US equities, which transforms complex data into actionable intelligence.
In other recent news, West Pharmaceutical Services reported strong financial results for the first quarter of 2026, significantly exceeding market expectations. The company achieved an adjusted earnings per share (EPS) of $2.13, surpassing the forecast of $1.68. Additionally, revenue reached $845 million, well above the anticipated $780.65 million. These results highlight the company’s robust performance during the period. Analysts have noted the positive earnings surprise, which may influence future assessments of the company’s financial health. The strong quarterly performance has been a focal point for investors, contributing to heightened interest in West Pharmaceutical Services. These developments are part of the company’s ongoing financial narrative.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.